Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pozelimab + Cemdisiran in Symptomatic Generalized Myasthenia Gravis
2020-003272-41Phase 3Active
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of pozelimab and cemdisiran in myasthenia gravis (MG) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Change in MG-ADL total score from baseline to week 24. Started Sep 2021; status: active.
02
Drugs
pozelimabcemdisiran
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2020-003272-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003272-41.